Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials

  • Thomas G. Nührenberg
  • Willibald Hochholzer
  • Kambis Mashayekhi
  • Miroslaw Ferenc
  • Franz-Josef Neumann
Original Paper
  • 28 Downloads

Abstract

Aims

The efficacy and safety of bivalirudin in patients undergoing percutaneous coronary intervention (PCI) for treatment of acute coronary syndromes (ACS) remains controversial despite recent evidence from large randomized-controlled trials (RCTs). Thus, this systematic review and meta-analysis sought to investigate the efficacy and safety of bivalirudin as compared to heparin in patients with ACS undergoing PCI.

Methods and results

Medline/PubMed, Cochrane Central Register of Controlled Trials, and Clinical Trials.gov databases were searched for RCTs. Primary endpoint was MACE consisting of all-cause death, myocardial infarction, and stroke within 30 days. Secondary endpoints were components of the primary endpoint and stent thrombosis. The primary safety endpoint was major bleeding. We identified 12 RCTs comprising 33,844 patients. Between bivalirudin and heparin, there were no significant differences for MACE (OR 1.06; 95% CI 0.96–1.17; p = 0.24), death, myocardial infarction, and stent thrombosis. Similar results were seen following stratification by use of glycoprotein inhibitors (GPI). Major bleeding trended to be less frequent in patients treated with bivalirudin. However, no safety benefit for bivalirudin was seen when use of GPI was balanced between groups (OR 0.88; 95% CI 0.67–1.16; p = 0.35; p for heterogeneity < 0.01).

Conclusions

Compared with heparin, bivalirudin was associated with a similar incidence of ischemic events following PCI for ACS. An association of bivalirudin with decreased bleeding was not seen with balanced use of GPI.

Keywords

Acute coronary syndrome Percutaneous coronary intervention Bivalirudin Heparin Glycoprotein inhibitors Meta-analysis 

Notes

Compliance with ethical standards

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest with regard to the submitted manuscript.

Supplementary material

392_2018_1251_MOESM1_ESM.docx (18 kb)
Supplementary material 1 (DOCX 17 KB)
392_2018_1251_MOESM2_ESM.docx (19 kb)
Supplementary material 2 (DOCX 18 KB)

References

  1. 1.
    Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ (2014) 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 64(24):e139-e228.  https://doi.org/10.1016/j.jacc.2014.09.017 CrossRefPubMedGoogle Scholar
  2. 2.
    Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P, Group ESCSD. (2018) 2017 esc guidelines for the management of acute myocardial infarction in patients presenting with st-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39(2):119–177.  https://doi.org/10.1093/eurheartj/ehx393 CrossRefPubMedGoogle Scholar
  3. 3.
    O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on Practice G (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127 (4):e362-425.  https://doi.org/10.1161/CIR.0b013e3182742cf6
  4. 4.
    Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, Baumgartner H, Gaemperli O, Achenbach S, Agewall S, Badimon L, Baigent C, Bueno H, Bugiardini R, Carerj S, Casselman F, Cuisset T, Erol C, Fitzsimons D, Halle M, Hamm C, Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS, Lip GY, Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints C, Luis Zamorano J, Management of acute coronary syndromes in patients presenting without persistent STSEotESoC (2016) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 37 (3):267–315.  https://doi.org/10.1093/eurheartj/ehv320 CrossRefPubMedGoogle Scholar
  5. 5.
    Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Acute C, Urgent Intervention Triage strategy trial I (2007) Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the acute catheterization and urgent intervention triage strategy (ACUITY) trial. Lancet 369 (9565):907–919.  https://doi.org/10.1016/S0140-6736(07)60450-4 CrossRefPubMedGoogle Scholar
  6. 6.
    Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R, Investigators H-AT (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Eng J Med 358(21):2218–2230.  https://doi.org/10.1056/NEJMoa0708191 CrossRefGoogle Scholar
  7. 7.
    Feldman A, Suleiman K, Bushari L, Yahalom M, Rozner E, Freedberg NA, Turgeman Y (2014) Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients at high risk for bleeding. Int J Angiol 23(4):227–232.  https://doi.org/10.1055/s-0034-1372244 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, Chen S, Jiang T, Yang P, Chen J, Jiang D, Jing Q, Liang Z, Liu H, Zhao X, Li J, Li Y, Xu B, Stone GW, Investigators B (2015) Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. Jama 313(13):1336–1346.  https://doi.org/10.1001/jama.2015.2323 CrossRefPubMedGoogle Scholar
  9. 9.
    Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, Laugwitz KL, Pache J, Ott I, Hausleiter J, Seyfarth M, Gick M, Antoniucci D, Schomig A, Berger PB, Mehilli J, Investigators I-RT (2011) Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 365(21):1980–1989.  https://doi.org/10.1056/NEJMoa1109596 CrossRefPubMedGoogle Scholar
  10. 10.
    Leonardi S, Frigoli E, Rothenbuhler M, Navarese E, Calabro P, Bellotti P, Briguori C, Ferlini M, Cortese B, Lupi A, Lerna S, Zavallonito-Parenti D, Esposito G, Tresoldi S, Zingarelli A, Rigattieri S, Palmieri C, Liso A, Abate F, Zimarino M, Comeglio M, Gabrielli G, Chieffo A, Brugaletta S, Mauro C, Van Mieghem NM, Heg D, Juni P, Windecker S, Valgimigli M, Investigators M (2016) Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. Bmj 354:i4935.  https://doi.org/10.1136/bmj.i4935 CrossRefPubMedGoogle Scholar
  11. 11.
    Patti G, Pasceri V, D’Antonio L, D’Ambrosio A, Macri M, Dicuonzo G, Colonna G, Montinaro A, Di Sciascio G (2012) Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the anti-thrombotic strategy for reduction of myocardial damage during angioplasty-bivalirudin vs heparin study). Am J Cardiol 110(4):478–484.  https://doi.org/10.1016/j.amjcard.2012.04.017 CrossRefPubMedGoogle Scholar
  12. 12.
    Schulz S, Richardt G, Laugwitz KL, Morath T, Neudecker J, Hoppmann P, Mehran R, Gershlick AH, Tolg R, Anette Fiedler K, Abdel-Wahab M, Kufner S, Schneider S, Schunkert H, Ibrahim T, Mehilli J, Kastrati A, Bavarian Reperfusion Alternatives Evaluation I (2014) Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. Eur Heart J 35 (34):2285–2294.  https://doi.org/10.1093/eurheartj/ehu182 CrossRefPubMedGoogle Scholar
  13. 13.
    Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, Andron M, Appleby C, Fisher M, Khand A, Kunadian B, Mills JD, Morris JL, Morrison WL, Munir S, Palmer ND, Perry RA, Ramsdale DR, Velavan P, Stables RH, Investigators H-Pt (2014) Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 384 (9957):1849–1858.  https://doi.org/10.1016/S0140-6736(14)60924-7 CrossRefPubMedGoogle Scholar
  14. 14.
    Steg PG, van ‘t Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, Ten Berg J, Van Grunsven P, Eggink GJ, Nibbe L, Zeymer U, Orto M, Nef H, Steinmetz J, Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D, Prats J, Clayton T, Pocock S, Hamon M, Goldstein P, Investigators E (2013) Campo dell’. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 369(23):2207–2217.  https://doi.org/10.1056/NEJMoa1311096 CrossRefPubMedGoogle Scholar
  15. 15.
    Valgimigli M, Frigoli E, Leonardi S, Rothenbuhler M, Gagnor A, Calabro P, Garducci S, Rubartelli P, Briguori C, Ando G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, van ‘t Hof A, Boccuzzi G, Omerovic E, Sabate M, Heg D, Juni P, Vranckx P, Investigators M (2015) Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 373(11):997–1009.  https://doi.org/10.1056/NEJMoa1507854 CrossRefPubMedGoogle Scholar
  16. 16.
    Zhang S, Gao W, Li H, Zou M, Sun S, Ba Y, Liu Y, Cheng G (2016) Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Int J Cardiol 209:87–95.  https://doi.org/10.1016/j.ijcard.2016.01.206 CrossRefPubMedGoogle Scholar
  17. 17.
    Cavender MA, Sabatine MS (2014) Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet 384(9943):599–606.  https://doi.org/10.1016/S0140-6736(14)61216-2 CrossRefPubMedGoogle Scholar
  18. 18.
    Verdoia M, Schaffer A, Barbieri L, Suryapranata H, De Luca G (2016) Bivalirudin versus unfractionated heparin in acute coronary syndromes: an updated meta-analysis of randomized trials. Revista espanola de cardiologia 69(8):732–745.  https://doi.org/10.1016/j.rec.2016.03.007 CrossRefPubMedGoogle Scholar
  19. 19.
    Capodanno D, Gargiulo G, Capranzano P, Mehran R, Tamburino C, Stone GW (2016) Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials. Eur Heart J Acute Cardiovasc Care 5(3):253–262.  https://doi.org/10.1177/2048872615572599 CrossRefPubMedGoogle Scholar
  20. 20.
    Erlinge D, Omerovic E, Frobert O, Linder R, Danielewicz M, Hamid M, Swahn E, Henareh L, Wagner H, Hardhammar P, Sjogren I, Stewart J, Grimfjard P, Jensen J, Aasa M, Robertsson L, Lindroos P, Haupt J, Wikstrom H, Ulvenstam A, Bhiladvala P, Lindvall B, Lundin A, Todt T, Ioanes D, Ramunddal T, Kellerth T, Zagozdzon L, Gotberg M, Andersson J, Angeras O, Ostlund O, Lagerqvist B, Held C, Wallentin L, Schersten F, Eriksson P, Koul S, James S (2017) Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med 377(12):1132–1142.  https://doi.org/10.1056/NEJMoa1706443 CrossRefPubMedGoogle Scholar
  21. 21.
    Pasala T, Gajulapalli RD, Bolen S, Bajaj NS, Gandhi S, Tandar A, Owan T, Welt FG (2016) Transradial access mitigates bleeding benefit offered by bivalirudin over heparin in patients undergoing percutaneous coronary intervention: insights from meta-analysis of randomized and observational studies. Int J Cardiol 221:601–608.  https://doi.org/10.1016/j.ijcard.2016.07.043 CrossRefPubMedGoogle Scholar
  22. 22.
    Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097.  https://doi.org/10.1371/journal.pmed.1000097 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    He P, Wei H, Wulasihan M, Yang YC, Liu Z, Ma Y, Mei C, Zhang L, Liu T, Wang S, Li L (2016) Comparisons of effectiveness and safety between bivalirudin and heparin with tirofiban in ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. Int J Clin Exp Med 9(12):23472–23481Google Scholar
  24. 24.
    Friedrich JO, Adhikari NK, Beyene J (2007) Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 7:5.  https://doi.org/10.1186/1471-2288-7-5 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Controll Clin Trials 7(3):177–188CrossRefGoogle Scholar
  26. 26.
    Chhatriwalla AK, Amin AP, Kennedy KF, House JA, Cohen DJ, Rao SV, Messenger JC, Marso SP, National Cardiovascular Data R (2013) Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. Jama 309 (10):1022–1029.  https://doi.org/10.1001/jama.2013.1556 CrossRefPubMedGoogle Scholar
  27. 27.
    Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schomig A, Kastrati A (2008) Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 51(7):690–697.  https://doi.org/10.1016/j.jacc.2007.10.040 CrossRefPubMedGoogle Scholar
  28. 28.
    Tudur Smith C, Marcucci M, Nolan SJ, Iorio A, Sudell M, Riley R, Rovers MM, Williamson PR (2016) Individual participant data meta-analyses compared with meta-analyses based on aggregate data. Cochrane Database Syst Rev 9:MR000007.  https://doi.org/10.1002/14651858.MR000007.pub3 PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Cardiology and Angiology IIUniversity Heart Center Freiburg—Bad KrozingenBad KrozingenGermany

Personalised recommendations